

AngioDynamics to Present at the Canaccord Genuity Cardiovascular, Diabetes and Obesity Conference

ALBANY, N.Y.--(BUSINESS WIRE)-- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today announced that it will present at the 5th Annual Canaccord Genuity Cardiovascular, Diabetes and Obesity Conference, to be held December 7-8, 2010, at the Nikko Hotel in San Francisco.

On Tuesday, December 7, at 2:30 p.m. PT, AngioDynamics' President and Chief Executive Officer Jan Keltjens will review the Company's business strategy and recent corporate developments.

To access the webcast during or after the event, please visit the investor relations portion of the Company's website at: <http://investors.angiodynamics.com>. The replay will be available for 15 days after the event.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. AngioDynamics' diverse product lines include market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 x1608
jgersuk@AngioDynamics.com

or
EVC Group, Inc.
Investor Relations:
Doug Sherk / Greg Gin, 415-896-6820
dsherk@evcgroup.com
ggin@evcgroup.com

Media:
Chris Gale, 646-201-5431
cgale@evcgroup.com

Source: AngioDynamics, Inc.

News Provided by Acquire Media